Balaji Amines Limited — Updates, 02-08-2025: Press Release

Balaji Amines reported Q1 FY26 consolidated revenue of ₹367 Cr and PAT of ₹37 Cr. Volumes saw sequential growth to 27,570 MT. However, EBITDA and PAT declined compared to previous quarters. Key expansion projects like DME and NMM are expected by FY2025-26, and Acetonitrile by FY2026-27, all via internal accruals. A major ₹750 Cr investment in its subsidiary, Balaji Speciality Chemicals, for new products like HCN and EDTA is also progressing, with commissioning targeted for FY2026-27. Management noted stable performance and anticipates margin expansion with industry recovery.